D. E. Shaw & Co., Inc. Rapt Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,048,186 shares of RAPT stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,048,186

Holding current value

$1.16 Million

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.76 - $3.75 $247,760 - $527,898	140,773 Added 15.51%	1,048,186 $2.11 Million
Q2 2024 Aug 14, 2024	BUY	$2.89 - $9.38 $1.84 Million - $5.98 Million	637,272 Added 235.9%	907,413 $2.77 Million
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $1.86 Million - $7.15 Million	270,141 New	270,141 $2.43 Million
Q2 2023 Aug 14, 2023	SELL	$16.06 - $21.61 $1.27 Million - $1.71 Million	-78,926 Reduced 82.16%	17,136 $320,000
Q1 2023 May 15, 2023	SELL	$17.19 - $30.8 $526,753 - $943,804	-30,643 Reduced 24.18%	96,062 $1.76 Million
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $443,223 - $669,735	27,225 Added 27.37%	126,705 $2.51 Million
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $1.79 Million - $3.03 Million	99,480 New	99,480 $2.39 Million
Q1 2022 May 16, 2022	SELL	$17.02 - $40.22 $1.17 Million - $2.76 Million	-68,648 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$29.5 - $39.5 $1.74 Million - $2.34 Million	-59,120 Reduced 46.27%	68,648 $2.52 Million
Q3 2021 Nov 15, 2021	BUY	$29.86 - $39.47 $2.39 Million - $3.15 Million	79,885 Added 166.83%	127,768 $3.97 Million
Q2 2021 Aug 16, 2021	BUY	$17.99 - $40.02 $861,415 - $1.92 Million	47,883 New	47,883 $1.52 Million

Others Institutions Holding RAPT

# of Institutions

104

Shares Held

27.1M

Call Options Held

26.7K

Put Options Held

2.4K

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $32.9M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account